This article has an online data supplement, which is accessible from this issue's table of contents online at www.atsjournals.org Vitamin D insufficiency and deficiency are highly prevalent in COPD patients, with the lowest levels being associated with the most severe airflow obstruction. 17 Since patients with the most severe COPD are also at highest risk for exacerbations 18 it is reasonable to posit that low levels of vitamin D might be an independent risk factor for AECOPDs. We therefore conducted a large observational cohort study to test this hypothesis in exacerbation-prone patients with COPD.
Methods
This study was a secondary analysis of data collected in a randomized, controlled trial testing the hypothesis that daily azithromycin decreases the frequency of AECOPD (ClinicalTrials.gov NCT00119860). 19 
Study participants
Inclusion criteria included a ratio of forced expiratory volume in one second 
Statistical methods
The pre-specified primary outcome of this study was the relationship between A pre-specified alternate analysis using annualized rates of AECOPDs was also conducted. Rates of AECOPDs were determined by dividing the number of
AECOPDs by person-years of follow-up and allowed for use of data from patients with multiple exacerbations over the one year of follow-up time. While the optimal analytic method of such data are not fully agreed upon 22, 23 we analyzed We also explored relationships between five 25(OH)D strata and AECOPD data, analyzing both time to first AECOPD using log-rank testing and annualized rates of AECOPDs using analysis of variance (ANOVA).
Our sample size of 973 patients (of whom 63% experienced an AECOPD)
provided 84% power with a two-tailed alpha error rate of 0.05 to detect a hazard ratio of 1.10 for a 10-unit change in 25(OH)D and time to first AECOPD.
Statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
Among 1142 participants in the trial, 25 (2.2%) had no follow-up after the baseline visit and were not included in this analysis. AECOPD data were therefore available for 1117 participants. Of these participants, 973 (87%) had viable plasma samples available for this secondary analysis of the relationship between baseline 25(OH)D and subsequent AECOPDs.
The demographic data of the trial participants are provided in Table 1 Figure 1 ). There was no significant association between clinical center and 25(OH)D levels (ANOVA p=0.254; Figure   1 ). Low 25(OH)D levels were associated with worse baseline health status as assessed by both Medical Outcomes Study 36-item Short Form (SF-36) and St.
George's Respiratory Questionnaire (SGRQ) data (see online data supplement).
These 973 participants experienced 1415 AECOPDs over one year. 360 (37%) remained AECOPD-free over one year, 278 (29%) had one AECOPD, 133 (14%) had two AECOPDs, and 202 (21%) had 3 or more AECOPDs.
In the primary analysis, 25(OH)D had no relationship to time to first AECOPD; for a 10 ng/mL increment in 25(OH)D, the estimated hazard ratio was 1.04, 95% An analysis of AECOPD rates stratified by 25(OH)D levels showed that participants with severe vitamin D deficiency (<10 ng/mL) had a higher mean rate of AECOPDs, but this difference was not statistically significant (Table 2 ). When 
Discussion
While some data suggest that low 25(OH)D levels are associated with an increased risk of respiratory infections, we found no relationship between baseline 25(OH)D levels and time to first AECOPD. The primary outcome used in this analysis was time to first AECOPD, but when we analyzed the data using 26 We used the same laboratory and the same liquid chromatography tandem mass spectroscopy methodology for 25(OH)D assays in both the previous LHS 3 study and the current study, so differences in analytic techniques would not explain the difference in seasonal effects. One potential explanation is that our previous LHS 3 sample was a group of patients with relatively mild COPD (mean FEV 1 of 72% of predicted), while patients in this current study had much more severe COPD (mean FEV 1 of 40% of predicted).
FEV 1 % predicted was not provided for the 24 patients in the UK study, but a mean FEV 1 of approximately 1.2 L suggests they also had severe COPD. One important note is that participants in the current study were selected for particularly high risk of AECOPDs (more than 80% experienced an AECOPD in the year prior to enrollment and there were 1415 exacerbations during follow-up 
